Regulatory

CLINUVEL
Posted by CLINUVEL
August 30, 2022

Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit

CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Dividend/Distribution – CUV

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4E & Annual Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More
CLINUVEL
Posted by CLINUVEL
July 25, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
June 23, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
June 14, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 25, 2022

Notice of change of interests of initial substantial holder

Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 20, 2022

Notice of initial substantial holder

Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 12, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo study

CLINUVEL today announced that it will start treatment of vitiligo patients with...

Read More
CLINUVEL
Posted by CLINUVEL
May 6, 2022

Notification regarding unquoted securities

Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 28, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
April 27, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 7, 2022

Initial Director’s Interest Notice

Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More